Skip to content
sellModerate cluster of 510b5-1 plan

Allan Steven Jacobson sold $2.1M of PTCT

director at PTC THERAPEUTICS, INC.. 26,000 shares at an average of $82.00, traded Nov 24, 2025, filed Nov 26, 2025.

Warning score
40
Value
$2.1M
26,000 shares
Holdings after
17,451
-112% from before
From 52-week low
+121%
low $36.19, close $79.83
From 52-week high
0%
high $79.83, as of Nov 24, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $2.1M at market
    +25
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    5 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PTCTOct 9, 2026 · close 64.70
Since filing Nov 26, 2025: -25.0%SPY +15.8% · excess -40.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001579003-25-000005, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 24, 2025MOption exercise
Common Stock10b5-1
+5,701$11.23$64k23,152Nov 26, 2025
Nov 24, 2025SOpen-market sale
Common Stock10b5-1
-5,701$80.13$457k17,451Nov 26, 2025
Nov 24, 2025MOption exercise
Common Stock10b5-1
+6,100$18.01$110k23,551Nov 26, 2025
Nov 24, 2025SOpen-market sale
Common Stock10b5-1
-6,100$80.15$489k17,451Nov 26, 2025
Nov 25, 2025MOption exercise
Common Stock10b5-1
+6,299$11.23$71k23,750Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-2,264$82.63$187k21,486Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-2,510$83.93$211k18,976Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-1,125$84.45$95k17,851Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-400$85.24$34k17,451Nov 26, 2025
Nov 25, 2025MOption exercise
Common Stock10b5-1
+7,900$18.01$142k25,351Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-2,460$82.58$203k22,891Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-3,502$83.38$292k19,389Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-1,238$84.47$105k18,151Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-700$85.32$60k17,451Nov 26, 2025
Nov 24, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-5,701$0.00$06,299Nov 26, 2025
Nov 24, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-6,100$0.00$07,900Nov 26, 2025
Nov 25, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-6,299$0.00$00Nov 26, 2025
Nov 25, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-7,900$0.00$00Nov 26, 2025

Related signals

Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
21Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$158k
2,500 shares
-0%
6Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Mark Elliott Boulding
EXEC. VP AND CLO
$133k
2,073 shares
-2%
27Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Glenn Steele Jr Md Phd
director
$782k
12,000 shares
-35%
28Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$1.3M
20,000 shares
-2%
20Weak
PTCTsell10b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$1.4M
20,000 shares
-1%
15Weak
PTCTsell10b5-1
PTC THERAPEUTICS, INC.
Eric Pauwels
CHIEF BUSINESS OFFICER
$1.6M
20,508 shares
-29%
33Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Eric Pauwels
CHIEF BUSINESS OFFICER
$3.3M
43,492 shares
-59%
2Weak
PTCTsell 510b5-1
PTC THERAPEUTICS, INC.
Emma Reeve
director
$58k
733 shares
-10%
33Weak
PTCTsell 410b5-1
PTC THERAPEUTICS, INC.
Matthew B. Klein
CHIEF EXECUTIVE OFFICER
$271k
3,428 shares
-1%
30Weak
PTCTsell 510b5-1
PTC THERAPEUTICS, INC.
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER
$2.9M
35,572 shares
-35%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Allan Steven Jacobson sold $2.1M of PTCT | InsiderTell